Abliva Logo

Abliva

Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.

ABLI | ST

Overview

Corporate Details

ISIN(s):
SE0002575340
LEI:
5493005YV22OTMUHZ183
Country:
Sweden
Address:
Medicon Village, 223 81 Lund
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Abliva is a clinical-stage biotechnology company that develops medicines for the treatment of primary mitochondrial diseases. These rare, congenital, and often severe conditions occur when the cell's ability to convert energy is impaired. The company is focused on discovering and developing therapies to restore mitochondrial function and improve the lives of patients. Its portfolio includes the lead drug candidate KL1333, which is being evaluated in the FALCON Phase II clinical study for adult patients with primary mitochondrial disease. Abliva aims to be a leader in the field of mitochondrial medicine.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-03-03 13:10
Delisting Announcement
Delisting of the shares of Abliva: last day of trading 17 March 2025
English 64.3 KB
2025-03-03 13:10
Delisting Announcement
Avnotering av aktierna i Abliva: sista handelsdag 17 mars 2025
Swedish 64.1 KB
2025-02-26 08:30
Pre-Annual General Meeting Information
Notice of Extraordinary General Meeting in Abliva AB (publ)
English 74.8 KB
2025-02-26 08:30
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i Abliva AB (publ)
Swedish 75.2 KB
2025-02-25 09:50
Delisting Announcement
Abliva applies for delisting and will convene an extraordinary general meeting
English 64.9 KB
2025-02-25 09:50
Delisting Announcement
Abliva ansöker om avnotering och kommer att kalla till extra bolagsstämma
Swedish 65.1 KB
2025-02-21 14:41
Declaration of Voting Results & Voting Rights Announcements
Swedish 9.6 KB
2025-02-21 08:30
Annual Report
Swedish 2.6 MB
2025-02-21 08:30
Annual Report
English 2.6 MB
2025-02-12 11:37
Major Shareholding Notification
Swedish 9.5 KB
2025-02-11 15:52
Major Shareholding Notification
Swedish 9.7 KB
2024-12-15 20:00
M&A Activity
Uttalande från Ablivas styrelse med anledning av Pharmings kontanta offentliga …
Swedish 83.3 KB
2024-12-15 20:00
M&A Activity
Statement by the Board of Directors of Abliva regarding the public cash offer f…
English 80.9 KB
2024-11-29 18:00
Quarterly Report
Swedish 2.9 MB
2024-11-29 18:00
Quarterly Report
English 2.9 MB

Automate Your Workflow. Get a real-time feed of all Abliva filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Abliva via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-07 David Bejker Other Sell 269,005 121,052.25 SEK
2024-05-31 Catharina Janzon Johansson Other Other 2,000,000 60,000.00 SEK
2024-05-28 David Laskow-Pooley Other Other 1,000,000 30,000.00 SEK
2023-07-13 David Laskow-Pooley Other Buy 54,128 11,664.58 SEK
2023-07-13 David Laskow-Pooley Other Buy 38,000 8,151.00 SEK
2023-07-13 David Laskow-Pooley Other Buy 36,064 7,807.86 SEK
2023-07-13 David Laskow-Pooley Other Buy 15,091 3,267.20 SEK
2023-07-13 David Laskow-Pooley Other Buy 11,901 2,588.47 SEK
2023-07-13 David Laskow-Pooley Other Buy 11,270 2,479.40 SEK
2023-07-13 David Laskow-Pooley Other Buy 11,275 2,474.86 SEK

Peer Companies

Company Country Ticker View
KOA SHOJI HOLDINGS CO.,LTD. Logo
Imports APIs and manufactures generic drugs for Japan's pharmaceutical industry.
Japan 9273
KOBAYASHI PHARMACEUTICAL  CO.,LTD. Logo
Manufactures OTC pharma, personal care, and household goods for niche consumer markets.
Japan 4967
Kohjin Bio Co., Ltd. Logo
A CDMO providing culture media & bioservices for cell therapy, research, and diagnostics.
Japan 177A
KOLON LIFE SCIENCE Inc. Logo
Develops gene therapies and manufactures APIs, providing global CDMO/CMO services.
South Korea 102940
Kolon TissueGene, Inc. Logo
Developing cell and gene therapies for orthopedic and degenerative disorders.
United States of America 950160
Develops animal health products and novel drugs for human cancer and autoimmune diseases.
South Korea 041960
KOREA ARLICO PHARM CO.,LTD. Logo
Manufactures generic drugs and provides CDMO services to a global market.
South Korea 260660
Develops and manufactures prescription (ETC) and over-the-counter (OTC) medicines for public health.
South Korea 014570
K Pharma,Inc. Logo
Develops iPS cell-based drugs and regenerative medicine for central nervous system disorders.
Japan 4896
Kringle Pharma,Inc. Logo
Develops regenerative HGF medicines for rare and intractable neurological diseases.
Japan 4884

Talk to a Data Expert

Have a question? We'll get back to you promptly.